Financial Data and Key Metrics Changes - SS&C Technologies reported record adjusted revenue of $1.655 billion for Q4 2025, an increase of 8% year-over-year, and adjusted diluted earnings per share of $1.69, reflecting an 18% increase [5][10] - Adjusted consolidated EBITDA reached a record $651 million, up 9%, with an adjusted EBITDA margin of 39.3% [5][11] - Cash from operating activities for the full year was $1.745 billion, up 26% year-over-year, with operating cash flow per share at $6.89, an increase of $1.42 from 2024 [6][12] Business Line Data and Key Metrics Changes - GIDS experienced a revenue growth of 13.2%, while GlobeOp saw a 9.6% revenue increase, contributing significantly to the overall performance [5][10] - Intralinks showed signs of improvement with modest growth in Q4, indicating potential momentum for 2026 [6] Market Data and Key Metrics Changes - The company is focusing on international growth opportunities, particularly in Australia, leveraging recent superannuation mandates [5] - The healthcare business is viewed as a long-term play, with expectations for future growth despite current headwinds [20] Company Strategy and Development Direction - The company is optimistic about the AI boom, viewing it as a tailwind for growth, and is rapidly deploying AI solutions to enhance efficiency and scalability [4][9] - SS&C is prioritizing share repurchases and is open to high-quality, accretive acquisitions, with over $1 billion allocated for share repurchases in 2025 [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of growth drivers, emphasizing long-term partnerships that create recurring revenue [8][9] - The company anticipates continued strong performance in 2026, with guidance for revenue in the range of $6.65 billion to $6.74 billion and organic growth of 5.1% at the midpoint [15][16] Other Important Information - The effective non-GAAP tax rate for Q4 2025 was 19.2%, with a full-year effective tax rate of 22% [12] - The company ended Q4 with $462 million in cash and cash equivalents and a net debt of $7 billion, resulting in a net leverage ratio of 2.8 times [13] Q&A Session Summary Question: What drove the weakness in the healthcare business? - Management noted that healthcare is a long-term play and highlighted the lumpy nature of large license sales, with optimism for future growth due to new technology [20][21] Question: Update on the Elevance relationship? - Management indicated that DomaniRx is ready for onboarding, but challenges exist due to the size and complexity of Elevance's existing relationships [22] Question: Insights on alternative fund administration growth? - Management confirmed strong organic growth in the alternative fund administration sector, with expectations for continued growth in 2026, partly driven by the acquisition of Curo Fund Services [25] Question: Outlook for the intelligent automation business? - Management expressed optimism for the intelligent automation business, noting that it is a key area for innovation and growth, particularly with AI advancements [26][27] Question: Organic growth guidance for 2026? - Management stated that the consistent organic growth guidance reflects a stronger business with more predictability and recurring revenue [31] Question: Competitive advantage against emerging AI fintechs? - Management emphasized the challenges of building a large organization compared to starting a fintech, highlighting the importance of regulatory compliance and established client relationships [32][33] Question: Medium-term outlook for wealth and investment management? - Management expressed optimism for the wealth management business, citing the strength of the Black Diamond platform and ongoing integration efforts [36][38] Question: M&A environment insights? - Management indicated ongoing interest in acquisitions, noting that they are well-positioned to pursue larger opportunities if the right targets are identified [39][40]